Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections

Jan Willem Alffenaar, Anne Grete Märtson, Scott K. Heysell, Jin Gun Cho, Asad Patanwala, Gina Burch, Hannah Y. Kim, Marieke G.G. Sturkenboom, Anthony Byrne, Debbie Marriott, Indy Sandaradura, Simon Tiberi, Vitali Sintchencko, Shashikant Srivastava, Charles A. Peloquin

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to progressive and life-threatening disease of multiple organs. Several factors such as increased testing and prevalence have made this an emerging infectious disease. Multiple guidelines have been published to guide therapy, which remains difficult owing to the complexity of therapy, the potential for acquired resistance, the toxicity of treatment, and a high treatment failure rate. Given the long duration of therapy, complex multi-drug treatment regimens, and the risk of drug toxicity, therapeutic drug monitoring is an excellent method to optimize treatment. However, currently, there is little available guidance on therapeutic drug monitoring for this condition. The aim of this review is to provide information on the pharmacokinetic/pharmacodynamic targets for individual drugs used in the treatment of nontuberculous mycobacteria disease. Lacking data from randomized controlled trials, in vitro, in vivo, and clinical data were aggregated to facilitate recommendations for therapeutic drug monitoring to improve efficacy and reduce toxicity.

Original languageEnglish (US)
Pages (from-to)711-725
Number of pages15
JournalClinical Pharmacokinetics
Issue number6
StatePublished - Jun 2021

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this